TMS1 Antibody

What is TMS1/ASC and what is its biological significance?

TMS1/ASC (Target of Methylation-induced Silencing 1/Apoptosis-associated Speck-like protein containing a CARD) is an intracellular signaling molecule with crucial roles in regulating apoptosis, nuclear factor-κB activation, and cytokine maturation . It contains both a pyrin domain (PYD) and a caspase recruitment domain (CARD), functioning as an adaptor protein in inflammasome assembly. Expression studies have revealed its presence across multiple tissues, with highest expression in peripheral blood leukocytes, lung, small intestine, spleen, thymus, and colon, while showing lower expression in placenta, liver, and kidney. Very low expression is observed in skeletal muscle, heart, and brain tissues . TMS1/ASC's significance extends to cancer biology, where its silencing through epigenetic mechanisms has been documented in breast tumors and is being investigated in glioblastoma multiforme .

What experimental applications are TMS1 antibodies validated for?

TMS1 antibodies have been extensively validated across multiple applications crucial for protein research. According to publication records, TMS1 antibodies have been successfully employed in:

The application versatility makes TMS1 antibodies valuable tools for investigating protein expression, localization, and interactions in both normal and pathological contexts .

How should TMS1 antibody dilutions be optimized for different applications?

Antibody dilution optimization is critical for achieving specific signal with minimal background. For TMS1 antibodies, recommended starting dilutions vary by application:

Each new experimental system requires antibody titration to determine optimal working dilutions. For antigen retrieval in IHC applications, TE buffer at pH 9.0 is suggested, though citrate buffer (pH 6.0) can serve as an alternative . The wide range for WB applications (1:5000-1:50000) indicates high sensitivity of some TMS1 antibodies, but actual performance will vary based on protein abundance in your samples and detection system used.

How can TMS1 antibodies be used to investigate inflammasome activation in different disease models?

TMS1/ASC plays a crucial role in inflammasome assembly, forming characteristic "specks" during activation that can be visualized using immunofluorescence with TMS1 antibodies. For investigating inflammasome activation:

• Speck Formation Quantification: Use IF with TMS1 antibodies (1:500 dilution) to visualize and quantify ASC speck formation following inflammasome stimulation. This approach allows assessment of the percentage of cells with activated inflammasomes.

• Co-localization Studies: Combine TMS1 antibodies with antibodies against other inflammasome components (e.g., NLRP3, caspase-1) to investigate co-localization and complex formation using confocal microscopy.

• Biochemical Fractionation: Use differential centrifugation to separate soluble and insoluble (speck-containing) fractions, followed by Western blotting with TMS1 antibodies to quantify inflammasome activation biochemically.

• Proximity Ligation Assays: Combine TMS1 antibodies with antibodies against interaction partners to visualize and quantify protein-protein interactions in situ, particularly useful for studying early events in inflammasome assembly.

When studying disease models, consider cell-type specific expression patterns of TMS1/ASC. For instance, while strongly expressed in myeloid cells, TMS1/ASC is also present in lung epithelial cells but absent in certain lymphoma cell lines like Jurkat T-cell lymphoma and Daudi Burkitt's lymphoma . This differential expression pattern may influence experimental design and interpretation of results across disease models.

What are the key considerations when validating TMS1 antibody specificity for epigenetic research?

When investigating TMS1/ASC in epigenetic regulation contexts, particularly where gene silencing occurs through methylation, antibody specificity becomes critically important. Consider these validation approaches:

• Positive and Negative Control Cells: Include cell lines with known TMS1/ASC expression status. HL-60 and U-937 leukemia cells express TMS1/ASC, while HeLa cervical carcinoma cells and MOLT-4 lymphocytic leukemia cells lack expression . Western blot analysis should show the expected 22-25 kDa band in positive but not negative control cells.

• Methylation Treatment Controls: Validate antibody performance following demethylating treatments (e.g., 5-aza-2'-deoxycytidine) that restore TMS1/ASC expression in silenced cells. The antibody should detect newly expressed protein after treatment.

• Knockdown/Knockout Validation: Implement siRNA/shRNA knockdown or CRISPR/Cas9 knockout of TMS1/ASC to confirm signal specificity. The antibody signal should diminish proportionally to the degree of knockdown.

• Recombinant Protein Controls: Include purified recombinant TMS1/ASC protein as a positive control for immunoblotting to confirm antibody recognition of the target protein.

• Peptide Competition Assays: Pre-incubate the antibody with immunizing peptide before application to samples. This should abolish specific signal if the antibody is truly specific.

When examining methylation-induced silencing of TMS1/ASC in cancer contexts, correlate protein expression data from TMS1 antibody studies with methylation analysis (e.g., bisulfite sequencing, methylation-specific PCR) of the TMS1/ASC promoter region to establish methylation-expression relationships .

How can structural prediction challenges affect TMS1 antibody epitope recognition and experimental design?

Antibody-epitope interactions can be significantly influenced by protein structure, and recent research highlights challenges in antibody structure prediction that may impact experimental outcomes:

• Epitope Accessibility: If the TMS1/ASC epitope recognized by an antibody is conformationally dependent, protein folding alterations due to experimental conditions may affect antibody binding. This is particularly relevant when using antibodies targeting domains involved in protein-protein interactions, such as the PYD or CARD domains of TMS1/ASC.

• Prediction Model Limitations: Current antibody structure prediction tools (e.g., ABlooper, IgFold, DeepAb) can produce models with inaccuracies including cis-amide bonds, D-amino acids, and structural clashes . These issues particularly affect predictions of complementarity-determining regions (CDRs), which are crucial for antigen binding.

• Structural Ensemble Considerations: The high conformational variability of antibody CDR loops, particularly CDR-H3, means a single static structure may not accurately represent the binding capabilities of an antibody . This variability can impact epitope mapping and binding affinity predictions for TMS1/ASC antibodies.

To address these challenges:

• Validate antibody binding under various denaturing and native conditions

• Use multiple antibodies targeting different epitopes of TMS1/ASC when possible

• Implement computational validation tools like "TopModel" to assess structural quality of antibody models if performing in silico analyses

• Consider that antibody binding may be affected by post-translational modifications or protein-protein interactions involving TMS1/ASC

Understanding these structural prediction limitations is particularly important when designing experiments involving conformational epitopes or when interpreting unexpected results in different experimental contexts.

What are the optimal sample preparation methods for detecting TMS1/ASC in different applications?

Sample preparation significantly impacts TMS1/ASC detection across different experimental platforms:

For Western Blotting:

• Lysis Buffer Selection: Use RIPA buffer supplemented with protease inhibitors for general applications. For detecting TMS1/ASC in inflammasome complexes, consider NP-40 buffer which better preserves protein-protein interactions.

• Protein Denaturation: Heat samples at 95°C for 5 minutes in Laemmli buffer containing β-mercaptoethanol. TMS1/ASC typically appears as a 22-25 kDa band on SDS-PAGE .

• Loading Control Selection: GAPDH or β-actin serve as suitable loading controls for total protein normalization.

For Immunohistochemistry:

• Fixation: 10% neutral-buffered formalin for 24-48 hours is standard for tissue samples.

• Antigen Retrieval: TE buffer at pH 9.0 is recommended as primary method, with citrate buffer (pH 6.0) as an alternative . Heat-induced epitope retrieval using pressure cooking or microwave methods typically yields better results than enzymatic retrieval.

• Blocking: 5-10% normal serum (species different from the primary antibody source) with 1% BSA for 1 hour at room temperature minimizes background.

For Immunoprecipitation:

• Antibody Amount: Use 0.5-4.0 μg antibody for 1.0-3.0 mg of total protein lysate .

• Bead Selection: Protein A/G beads work effectively for rabbit polyclonal TMS1 antibodies.

• Pre-clearing: Pre-clear lysates with beads alone to reduce non-specific binding.

For Immunofluorescence:

• Fixation Options: 4% paraformaldehyde (10 minutes at room temperature) preserves cellular architecture, while methanol fixation (5 minutes at -20°C) may better expose certain epitopes.

• Permeabilization: 0.1% Triton X-100 for 5-10 minutes allows antibody access to intracellular TMS1/ASC.

• Imaging Considerations: When visualizing ASC specks, confocal microscopy provides better resolution than conventional fluorescence microscopy.

Each application requires optimization specific to the experimental system and antibody used. Pilot experiments comparing different preparation methods are highly recommended.

How should researchers address cross-reactivity concerns when using TMS1 antibodies?

Cross-reactivity can compromise experimental results and lead to misinterpretation of data. For TMS1 antibodies, implement these strategies to address potential cross-reactivity:

• Species Compatibility Verification: Available TMS1 antibodies show confirmed reactivity with human samples , with cited reactivity in pig, canine, and bovine samples . When working with non-human models, perform preliminary validation:

  • Compare observed molecular weight with species-specific predicted weight

  • Include human positive control samples for comparison

  • Verify with orthogonal methods (e.g., mass spectrometry)

• Multi-antibody Approach: Utilize antibodies from different manufacturers or those targeting different epitopes of TMS1/ASC. Concordant results across multiple antibodies increase confidence in specificity.

• Genetic Validation: Implement siRNA knockdown, CRISPR/Cas9 knockout, or overexpression systems as definitive controls. The signal should correspondingly decrease or increase if the antibody is specific.

• Peptide Competition Assays: Pre-incubate the antibody with blocking peptide (typically the immunogen) before application. Specific signals should be substantially reduced or eliminated.

• Isotype Controls: Include appropriate isotype controls (e.g., rabbit IgG for rabbit polyclonal antibodies) at equivalent concentrations to rule out non-specific binding from the antibody class itself.

• Tissue/Cell Panel Testing: Test antibody performance across a panel of tissues/cells with known differential expression of TMS1/ASC. For example, test against HL-60 and U-937 cells (positive) versus Jurkat T-cell lymphoma and Daudi Burkitt's lymphoma cells (negative) .

Document all validation steps in publications to support the reliability of results and facilitate reproducibility by other researchers.

What are the recommended storage and handling protocols to maintain TMS1 antibody performance?

Proper storage and handling significantly impact antibody stability and performance. For TMS1 antibodies:

Storage Recommendations:

• Temperature: Store at -20°C for long-term stability. Antibodies in glycerol buffer (e.g., PBS with 50% glycerol, pH 7.3) can be stored at -20°C without freeze-thaw cycles causing significant damage .

• Aliquoting: For antibodies without stabilizers (like glycerol), divide into small working aliquots before freezing to minimize freeze-thaw cycles. For antibodies in 50% glycerol, aliquoting is generally unnecessary for -20°C storage .

• Preservatives: Typical formulations include 0.02-0.09% sodium azide as a preservative . Note that sodium azide can inhibit HRP activity in some detection systems, so dilute sufficiently before use in such applications.

Handling Protocols:

• Thawing: Thaw frozen antibodies completely at room temperature or 4°C before use. Avoid repeated freeze-thaw cycles by preparing working aliquots.

• Working Solutions: Prepare diluted working solutions in freshly made buffer immediately before use. For prolonged experiments, working solutions can typically be stored at 4°C for up to one week with minimal loss of activity.

• BSA Addition: Some TMS1 antibody formulations contain 0.1-1% BSA as a stabilizer . For antibodies without BSA, consider adding 0.1-0.5% BSA to working solutions to improve stability.

• Centrifugation: Briefly centrifuge antibody vials before opening to collect liquid at the bottom and avoid loss of material.

Performance Monitoring:

• Positive Controls: Include known positive controls in each experiment to monitor antibody performance over time.

• Working Concentration Re-optimization: Periodically re-optimize working concentrations, especially after prolonged storage or when using a new lot.

• Shelf-life: While manufacturers typically guarantee 12 months from date of dispatch , many antibodies remain functional well beyond this period when properly stored. Document lot numbers and acquisition dates to track performance over time.

Following these recommendations will help maintain antibody activity and ensure consistent experimental results across studies.

How can researchers address weak or absent signal in TMS1 Western blot experiments?

When confronted with weak or absent TMS1/ASC signals in Western blotting, systematically investigate these potential causes and solutions:

• Protein Expression Levels: TMS1/ASC is expressed at low levels in many tissues . Consider:

  • Using cell lines with known high expression (HL-60, A549, Raji, U-937, THP-1)

  • Increasing sample loading amount (50-80 μg total protein)

  • Employing enrichment techniques like immunoprecipitation before Western blotting

• Antibody Concentration: TMS1 antibodies can be used at dilutions ranging from 1:5000 to 1:50000 , indicating high sensitivity. If signal is weak:

  • Start with more concentrated solutions (1:1000-1:5000)

  • Titrate the antibody to determine optimal concentration for your specific sample

  • Extend primary antibody incubation to overnight at 4°C

• Detection System Sensitivity:

  • Switch to more sensitive detection methods (ECL Plus or SuperSignal West Femto)

  • Consider fluorescent-based detection systems that may offer better signal-to-noise ratios

  • Extend film exposure times incrementally (30 seconds to 5 minutes)

• Transfer Efficiency:

  • Verify transfer with reversible staining (Ponceau S)

  • Adjust transfer conditions for small proteins (reduce transfer time or voltage)

  • Consider semi-dry transfer systems which can be more efficient for smaller proteins

• Epitope Accessibility:

  • Ensure complete denaturation (increase boiling time to 10 minutes)

  • Try different reducing agents (DTT instead of β-mercaptoethanol)

  • Test non-reducing conditions if the epitope is potentially sensitive to reduction

• Sample Preparation:

  • Include multiple protease inhibitors in lysis buffer

  • Process samples quickly at 4°C to minimize degradation

  • Consider alternative lysis buffers if protein solubilization is an issue

• Epigenetic Silencing:

  • TMS1/ASC can be silenced by methylation in some cancer cells

  • Treatment with demethylating agents (5-aza-2'-deoxycytidine) may restore expression

Document all troubleshooting steps systematically to identify the most effective approach for your specific experimental system.

What strategies can improve TMS1 antibody performance in immunohistochemistry applications?

Optimizing TMS1 antibody performance in immunohistochemistry requires addressing several technical aspects:

• Antigen Retrieval Optimization:

  • Primary recommendation: TE buffer at pH 9.0 using heat-induced epitope retrieval

  • Alternative approach: Citrate buffer at pH 6.0

  • Compare multiple retrieval methods side-by-side (microwave, pressure cooker, water bath)

  • Optimize retrieval time (10-30 minutes) and temperature

• Signal Amplification Techniques:

  • Implement polymer-based detection systems for enhanced sensitivity

  • Consider tyramide signal amplification (TSA) for low-abundance targets

  • Use biotin-free detection systems to eliminate endogenous biotin background

  • Extend chromogen development time with monitoring to optimize signal-to-noise ratio

• Background Reduction Strategies:

  • Include blocking steps for endogenous peroxidase (3% H₂O₂, 10 minutes)

  • Block endogenous biotin with avidin/biotin blocking kit if using biotin-based detection

  • Use species-specific serum (5-10%) with 1% BSA for blocking

  • Include 0.1-0.3% Triton X-100 in antibody diluent to reduce non-specific binding

• Antibody Incubation Parameters:

  • Test both 1-hour room temperature and overnight 4°C incubations

  • Optimize humidity during incubation to prevent section drying

  • Use antibody dilutions within recommended range (1:200-1:1000)

  • Consider addition of 0.05% Tween-20 to antibody diluent

• Tissue Processing Considerations:

  • Limit fixation time to 24-48 hours when possible

  • Use consistent section thickness (4-5 μm optimal for most applications)

  • Process control tissues alongside experimental samples

  • Consider using freshly cut sections rather than stored slides

• Controls Implementation:

  • Include positive control tissues with known TMS1/ASC expression

  • Implement negative controls by omitting primary antibody

  • Include isotype controls at equivalent concentration to primary antibody

  • Consider peptide competition controls to confirm specificity

By systematically optimizing these parameters, researchers can achieve specific and reproducible TMS1/ASC staining in tissue sections for accurate analysis of expression patterns in normal and pathological samples.

How can researchers validate conflicting results between different TMS1 antibody clones or manufacturers?

When faced with discrepancies between results obtained using different TMS1 antibody clones or manufacturers, implement this systematic validation approach:

• Epitope Mapping Analysis:

  • Determine the specific epitopes recognized by each antibody

  • Assess whether different antibodies target distinct domains of TMS1/ASC (PYD vs. CARD domains)

  • Consider whether post-translational modifications might affect epitope accessibility

  • Evaluate whether conformational changes in different experimental conditions might differentially affect epitope exposure

• Cross-Validation with Orthogonal Methods:

  • Complement antibody-based detection with mRNA expression analysis (qRT-PCR, RNA-seq)

  • Employ mass spectrometry for protein identification and quantification

  • Use fluorescent protein tagging of TMS1/ASC in cell models

  • Implement proximity ligation assays for detecting protein-protein interactions

• Controlled Comparison Experiments:

  • Test all antibodies simultaneously on identical samples

  • Use consistent protocols across antibody comparisons

  • Include multiple positive and negative control samples

  • Perform side-by-side dilution series to assess sensitivity differences

• Genetic Validation Studies:

  • Implement siRNA/shRNA knockdown of TMS1/ASC

  • Create CRISPR/Cas9 knockout cell lines as definitive negative controls

  • Develop overexpression systems to assess antibody saturation characteristics

  • Utilize inducible expression systems to create a gradient of expression levels

• Selective Enrichment Approaches:

  • Perform immunoprecipitation followed by mass spectrometry to confirm target identity

  • Use recombinant TMS1/ASC protein spiking experiments

  • Apply subcellular fractionation to assess compartment-specific detection

  • Implement peptide competition assays with specific immunizing peptides

• Manufacturer Communication:

  • Contact manufacturers regarding clone specifics and validation data

  • Request information about known cross-reactivity and limitations

  • Inquire about production methods (monoclonal vs. polyclonal)

  • Discuss specific application optimizations recommended by manufacturers

• Documentation and Reporting:

  • Maintain detailed records of all validation experiments

  • Document lot numbers, dilutions, and specific protocols

  • Report discrepancies in publications to alert the research community

  • Consider publishing validation studies if discrepancies are significant

This comprehensive validation approach will help distinguish technical artifacts from true biological differences and guide selection of the most appropriate antibody for specific experimental applications.